Drugs in Dev. Infections and Infectious Diseases
IND Enabling
Taiwan 
Lead Product(s) : Hydroxychloroquine Sulphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Phase I randomized, vehicle-controlled, blinded study will evaluate the safety, tolerability, and pharmacokinetics of single ascending doses of inhaled TLC19 in 30 healthy volunteers.
Product Name : TLC19
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 10, 2020
Lead Product(s) : Hydroxychloroquine Sulphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Antroquinonol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GBC’s Antroquinonol had been selected in the top 21 candidates of best treating projects in the first round of selection in global solicitation of Covid-19 pneumonia treatment projects.
Product Name : Hocena
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
April 16, 2020
Lead Product(s) : Antroquinonol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Silmitasertib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This is a phase II multi-center, randomized, two-armed controlled interventional prospective study. The objective of this study is to assess the safety, clinical benefit, and anti-viral activity of Silmitasertib in up to 40 patients with severe COVID-19.
Product Name : CX-4945
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 11, 2020
Lead Product(s) : Silmitasertib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
